Intellia Therapeutics (NTLA) Misses Q2 EPS by 30c

Intellia Therapeutics (NASDAQ: NTLA) reported Q2 EPS of ($1.52), $0.30 worse than the analyst estimate of ($1.22). Revenue for the quarter came in at $6.96 million versus the consensus estimate of $19.68 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Apollo Private Credit Fund caps redemptions at 5% - Bloomberg
• Japan's Katayama, Us Treasury's Bessent Hold Online Talks, Source Says - Reuters